lanthanum
Approved
Oct 26, 2004
Lanthanum hydroxide (La(OH)3) is a rare novel earth compound which has so far been fabricated with various morphologies such as nanopowders, nanotubes, nanowires, nanorods and nanobelts from different methods like solvothermal, hydrothermal, sol-gel and template assisted routes. This compound has many attractive applications in gas-exhaust convectors, optical coatings, catalysts, superconductors, hydrogen storage materials and next generation of high dielectric constant gate dielectrics. It is a useful carrier precipitate for a number of ions. It was applied to the collection of traces of aluminum, bismuth, gold, iridium, iron, lead, thallium and titanium in silver metal. It is a predecessor Lanthanum oxide, which has a great interest as catalyst material. — NCATS
Clinical trial activity
42 trials · 34 clinical orgs · 8 marketing orgs
Earliest trial started Oct 1, 2002 (NCT00150540)
Timeline
2000s
2010s
- Sep 24, 2014
Shire — First NDA Organization
- Sep 24, 2014
Shire — NDA Organization
- Aug 11, 2017
Natco Pharma — Marketing Organization
2020s
- Jan 24, 2022
Invagen Pharms — Marketing Organization
- Jan 24, 2022
Cipla — Marketing Organization
- Jan 27, 2022
Barr Laboratories — Marketing Organization
- Jan 27, 2022
Teva — Marketing Organization
- Mar 13, 2025
Alkem Labs Ltd — Marketing Organization
Indications
Approved for
Studied for
- Bone Diseases, Metabolic · Phase 4
- Calciphylaxis · Phase 1
- Cardiovascular Diseases · Phase 4
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 3
- Dialysis · Phase 2
- Healthy Volunteers · Phase 1
- Hyperoxaluria · Phase 3
- Hyperphosphatemia · Phase 4
- Kidney Diseases · Phase 4
- Kidney Failure, Chronic · Phase 4
- Nephrolithiasis · Phase 3
- Pharmacology, Clinical · Phase 1
- Renal Dialysis · Phase 3
- Renal Insufficiency, Chronic · Phase 4
- Serum · Phase 4
Mechanism of action
- PhosphateSEQUESTERING AGENT
phosphate
Approval history
- approvedOct 26, 2004
Chemistry & pharmacology
SMILES
[La+3]- Mol. weight
- 138.90547 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaLanthanum ↗
- NCATSO7FU5X12W5 ↗
- ChEMBLCHEMBL2096647 ↗
Also known as
- bay 77-1931
- bay 77-1931
- fosrenol
- fosrenol
- fosrenol
- fosrenol
- fosrenol
- la2(co3)3
- lanthanum(3+) carbonate
- lanthanum(3+) carbonate
- lanthanum carbonate
- lanthanum carbonate
- lanthanum carbonate
- lanthanum carbonate
- lanthanum carbonate
- lanthanum carbonate
- lanthanum carbonate
- lanthanum carbonate anhydrous
- lanthanum carbonate anhydrous
- lanthanum carbonate hydrate
- lanthanum carbonate hydrate
- lanthanum (iii) carbonate
- lanthanum (iii) carbonate
- lanthanum sesquicarbonate
- lanthanum sesquicarbonate
- lantharenol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04440696 | Phase 1/Phase 2 (Phase 2) | Oct 21, 2020 | Government of China, Jilin University, Jinlin University |
| NCT03346369 | Phase 3 | Aug 18, 2017 | Free University of Brussels |
| NCT02952040 | Phase 1 | Nov 1, 2016 | Astellas, FibroGen |
| NCT03136705 | Phase 1 | Feb 3, 2016 | Northwestern University |
| NCT03074058 | Phase 1 | Jun 10, 2015 | Bayer |
| NCT02258074 | Phase 3 | Mar 1, 2015 | John Kusek, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), University of Pittsburgh, University of Rochester |
| NCT02209636 | Phase 4 | Sep 15, 2014 | Department of Veteran Affairs |
| NCT02237534 | Phase 4 | Sep 1, 2014 | Bayer, Osaka University |
| NCT01696279 | Phase 2 | Feb 11, 2013 | Shire |
| NCT01581996 | N/A | Mar 1, 2012 | Los Angeles Biomedical Research Institute |
| NCT01578200 | Phase 3 | Dec 1, 2011 | Showa University, Translational Research Informatics Center, Kobe, Hyogo, Japan |
| NCT01845090 | Phase 4 | Aug 1, 2011 | Camillians Saint Mary's Hospital Luodong, Saint Mary's hospital, Lotung |
| NCT01357317 | Phase 3 | Jun 1, 2011 | Department of Veteran Affairs, Shire |
| NCT01341678 | N/A | Apr 1, 2011 | Denver Nephrologists, P.C. |
| NCT03451019 | Phase 4 | Mar 1, 2011 | Medical University of Lodz, Shire |
| NCT01289626 | Phase 1 | Feb 1, 2011 | Shire, University of Wisconsin |
| NCT01128179 | Phase 2 | Nov 1, 2010 | Shire |
| NCT01187628 | Phase 3 | Sep 1, 2010 | Bayer, Shire |
| NCT01110629 | Phase 3 | Jun 1, 2010 | Bayer, Shire |
| NCT01053676 | Phase 1 | Jan 1, 2010 | Bayer |
Organizations
Research & Development (34)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shire | For profit | 23 | 13 | 5 | 2002 |
| Bayer | For profit | 9 | 8 | 4 | 2005 |
| Northwestern University | Academic/Hospital | 3 | 1 | 3 | 2007 |
| Denver Nephrologists, P.C. | Academic/Hospital | 2 | 2 | 1 | 2009 |
| Department of Veteran Affairs | Government | 2 | 2 | 2 | 2011 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 2 | 0 | 2 | 2009 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 2 | 2009 |
| University of Illinois at Chicago | Academic/Hospital | 2 | 2 | 2 | 2007 |
| University of Miami | Academic/Hospital | 2 | 1 | 1 | 2007 |
| Astellas | For profit | 1 | 1 | 1 | 2016 |
| Camillians Saint Mary's Hospital Luodong | Academic/Hospital | 1 | 1 | 1 | 2011 |
| FibroGen | For profit | 1 | 0 | 1 | 2016 |
| Free University of Brussels | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Fresenius | For profit | 1 | 0 | 1 | 2009 |
| Genzyme | For profit | 1 | 0 | 1 | 2009 |
| Government of China | Government | 1 | 1 | 1 | 2020 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Ineos Healthcare Limited | For profit | 1 | 1 | 1 | 2009 |
| Jilin University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Jinlin University | Academic/Hospital | 1 | 0 | 1 | 2020 |
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alkem Labs Ltd | For profit | MKTG | Mar 13, 2025 |
| Barr Laboratories | For profit | MKTG | Jan 27, 2022 |
| Cipla | For profit | MKTG | Jan 24, 2022 |
| Invagen Pharms | For profit | MKTG | Jan 24, 2022 |
| Natco Pharma | For profit | MKTG | Aug 11, 2017 |
| Shire | For profit | SYN | Oct 26, 2004 |
| Shire | For profit | NDA | Sep 24, 2014 |
| Takeda | For profit | MKTG | Oct 26, 2004 |
| Takeda | For profit | NDA2 | Oct 26, 2004 |
| Teva | For profit | MKTG | Jan 27, 2022 |